Phase 1/2RecruitingAge-related condition
Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, PK and Efficacy of SCT520FF in Patients With nAMD
A Multicenter, Dose-escalation and Dose-expansion, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy Characteristics of SCT520FF in Patients With Neovascular Age-related Macular Degeneration
- Sponsor
- Sinocelltech Ltd. (Industry)
- Enrollment
- 82 planned
- Conditions
- nAMD
- Interventions
- SCT520FF; SCT520FF; SCT520FF; EYLEA 2 MG
- Ages
- adults, older adults
- Registry
- NCT06672536
Full record on ClinicalTrials.gov
From the registry
Multicenter, open-label, multi-dose study to evaluate the safety and tolerability in patients with nAMD treated with SCT520FF.
Primary outcomes
- Treatment emergent adverse events(TEAE)
- Treatment-related treatment emergent adverse events(TRAE)
- Serious adverse event(SAE)
- Adverse event of special interest(AESI)
History
Study completion expected
Primary completion
Last registry update
Started
Registered